Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' labile copper assay (Mayo ID: LBCS) improves upon standard blood tests for Wilson's disease. The new test measures not just overall copper but also the fraction of copper that is bioavailable, or labile bound.

(00:32)
Can you tell us a little bit about yourself and your background?

(01:33)
 Could you give us a brief overview of this assay?

(02:47)
 Which patients should have this testing, and when should it be performed?

(03:48)
 How would the results be used in patient care?